The record
| Class | glp1 agonist |
|---|---|
| Also known as | Trulicity, LY2189265 |
| Chain length | - |
| Molecular weight | 63,000 Da |
| Half-life | ~5 days (120 hours) |
| Route | SC (autoinjector pen) |
| Studied for | Type 2 diabetes mellitus; Cardiovascular risk reduction in T2DM; Weight management (investigational) |
| Research use | GLP-1 signaling research, incretin biology, beta cell function studies |
| What has been shown | HbA1c reduction: 1.1-1.6%; Weight loss: 2.5-4.6 kg; Cardiovascular benefit:; Once-weekly dosing improves adherence |
| How it works | GLP-1 receptor agonist fusion protein. Activates GLP-1R coupled to adenylyl cyclase in pancreatic beta cells, increasing cAMP and leading to: (1) Glucose-dependent insulin secretion, (2) Decreased glucagon secretion, (3) Delayed gastric emptying, (4) Reduced food intake via CNS satiety signaling, (5) Potential cardiovascular benefits. The Fc fusion provides extended half-life for weekly dosing. |
| Patent status | Eli Lilly patents |
| Regulatory status | FDA approved 2014 |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Glucose Regulation Support (affection, 82%)
- Cardiovascular risk reduction in T2DM (illness, 100%)
- CV risk reduction in T2D with CVD (illness, 40%)
- NASH/fatty liver (illness, 60%)
- Type 2 diabetes (illness, 40%)
- Type 2 diabetes mellitus (illness, 100%)
- Weight management (illness, 100%)
- High blood sugar (symptom, 100%)